CoChat

Selective Reversible Inhibition of Liver Carnitine Palmitoyl-Transferase 1 by Teglicar Reduces Gluconeogenesis and Improves Glucose Homeostasis

Open access

The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: We have developed a new antihyperglycemic agent (teglicar) through the selective and reversible inhibition of the liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1). RESEARCH DESIGN AND METHODS: Glucose production was investigated in isolated hepatocytes and during pancreatic clamps in healthy rats. Chronic treatments on C57BL/6J, db/db, high-fat fed mice, and rats were performed to understand glucose metabolism and insulin sensitivity. RESULTS: In isolated hepatocytes, teglicar concentration dependently reduced ketone bodies and glucose production up to 72 and 50%, respectively. In rats, teglicar reduced the endogenous glucose production (−62%) without affecting peripheral glucose utilization. Heart 2-[3H]deoxyglucose uptake in mice was also not affected, confirming in vivo the drug selectivity toward L-CPT1. Chronic treatment in db/db mice (50 mg/kg/bid; 45 days) reduced postabsorptive glycemia (−38%), water consumption (−31%), and fructosamine (−30%). Such antidiabetic activity was associated with an improved insulin sensitivity assessed by the insulin tolerance test. A significant 50% increase in hepatic triglyceride content (HTGC) was found, although plasma alanineaminotransferase was not altered. In addition, long-term teglicar administration to high-fat fed C57BL/6J mice normalized glycemia (−19%) and insulinemia (−53%). Long-term teglicar administration (30 days, 80 mg/kg) in healthy overnight-fasted rats slightly reduced basal glycemia (−20%, ns), reduced basal insulin levels by 60%, doubled triglycerides, and increased free-fatty acids (+53%). HTGC was markedly increased, but liver and peripheral insulin sensitivity assessed by hyperinsulinemiceuglycemic clamp were not affected. CONCLUSIONS: Teglicar, in vitro and in animal models, reduces gluconeogenesis and improves glucose homeostasis, refreshing the interest in selective and reversible L-CPT1 inhibition as a potential antihyperglycemic approach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db10-0346

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. A: Teglicar-dependent suppression of glucose and ketone bodies production by hepatocytes isolated from 16-h-fasted rats and incubated in presence of 10:1 lactate/pyruvate and 1 mmol/L oleate. B: Relationship between hepatocytes glucose production and the concentration of pyruvate/lactate in Krebs medium containing 1 mmol/L oleate in the presence or absence of 10 μmol/L teglicar. Each point represents the mean ± SE from eight different hepatocyte preparations in triplicate: ***P < 0.001; **P < 0.01 vs. control (CTRL) + oleate.
FIG. 1. A: Teglicar-dependent suppression of glucose and ketone bodies production by hepatocytes isolated from 16-h-fasted rats and incubated in presence of 10:1 lactate/pyruvate and 1 mmol/L oleate. B: Relationship between hepatocytes glucose production and the concentration of pyruvate/lactate in Krebs medium containing 1 mmol/L oleate in the presence or absence of 10 μmol/L teglicar. Each point represents the mean ± SE from eight different hepatocyte preparations in triplicate: ***P < 0.001; **P < 0.01 vs. control (CTRL) + oleate.CC BY-NC-ND · PubMed Central
FIG. 2. A: Pancreatic clamp procedure involves the infusion of 0.4 μCi/min [3-3H]glucose, 1.5 μg/kg/min somatostatin, and 0.7 mU/kg/min insulin. Control rats received saline throughout the experiment, whereas teglicar infusion was started at 120'. Rats receiving the drug also received glucose to prevent hypoglycemia. B: Representation of teglicar-induced drop in glycemia during pancreatic clamp. Euglycemia is restored by glucose coinfusion. C: Rates of glucose production before (EGP1) and during (EGP2) the infusion of teglicar (white bars) or saline (black bars) in postabsorptive SD rats. The box plots indicate the mean ± SE from five different pancreatic clamps/group. *P < 0.05 vs. saline.
FIG. 2. A: Pancreatic clamp procedure involves the infusion of 0.4 μCi/min [3-3H]glucose, 1.5 μg/kg/min somatostatin, and 0.7 mU/kg/min insulin. Control rats received saline throughout the experiment, whereas teglicar infusion was started at 120'. Rats receiving the drug also received glucose to prevent hypoglycemia. B: Representation of teglicar-induced drop in glycemia during pancreatic clamp. Euglycemia is restored by glucose coinfusion. C: Rates of glucose production before (EGP1) and during (EGP2) the infusion of teglicar (white bars) or saline (black bars) in postabsorptive SD rats. The box plots indicate the mean ± SE from five different pancreatic clamps/group. *P < 0.05 vs. saline.CC BY-NC-ND · PubMed Central
FIG. 3. A: Heart 2-DG uptake in C57BL/6J mice after a single administration of teglicar (50 mg/kg) or etomoxir (50 mg/kg). The box plots are expressed as micromoles of 2-DG incorporated per 100 grams wet tissue per minute ± SE obtained from eight animals/group. ***P < 0.001 vs. controls. B: Effect of long-term (30 days) teglicar administration (100 mg/kg/day) on heart 2-DG uptake, heart weight, and heart triglyceride (TG) content in C57BL/6J mice. The box plots are expressed in percentage with respect to controls ± SE obtained from six animals/group.
FIG. 3. A: Heart 2-DG uptake in C57BL/6J mice after a single administration of teglicar (50 mg/kg) or etomoxir (50 mg/kg). The box plots are expressed as micromoles of 2-DG incorporated per 100 grams wet tissue per minute ± SE obtained from eight animals/group. ***P < 0.001 vs. controls. B: Effect of long-term (30 days) teglicar administration (100 mg/kg/day) on heart 2-DG uptake, heart weight, and heart triglyceride (TG) content in C57BL/6J mice. The box plots are expressed in percentage with respect to controls ± SE obtained from six animals/group.CC BY-NC-ND · PubMed Central
FIG. 4. ITT in db/db mice after teglicar treatment. The small bar plot indicates the AUC (0–60 min) of glycemia during the ITT. Teglicar, black bar and circles; control, white bar and triangles. Data are expressed as percentage variation from initial glucose and in the bar plot as milligrams per deciliters per minute. Each point indicates the mean ± SE of eight mice. *P < 0.05 vs. controls.
FIG. 4. ITT in db/db mice after teglicar treatment. The small bar plot indicates the AUC (0–60 min) of glycemia during the ITT. Teglicar, black bar and circles; control, white bar and triangles. Data are expressed as percentage variation from initial glucose and in the bar plot as milligrams per deciliters per minute. Each point indicates the mean ± SE of eight mice. *P < 0.05 vs. controls.CC BY-NC-ND · PubMed Central
FIG. 5. Blood glucose levels during OGTT test on 5-h fasted male C57BL/6J mice fed with a high-fat diet and treated with teglicar (ST1326, 30 mg/kg, twice per day) for 15 days, at 5 h from last treatment. Means are ± SE (n = 6 for high-fat diet and low-fat diet; n = 5 for high-fat diet + teglicar). ***P < 0.001; **P < 0.01 vs. high-fat diet group.
FIG. 5. Blood glucose levels during OGTT test on 5-h fasted male C57BL/6J mice fed with a high-fat diet and treated with teglicar (ST1326, 30 mg/kg, twice per day) for 15 days, at 5 h from last treatment. Means are ± SE (n = 6 for high-fat diet and low-fat diet; n = 5 for high-fat diet + teglicar). ***P < 0.001; **P < 0.01 vs. high-fat diet group.CC BY-NC-ND · PubMed Central
FIG. 6. A: Representative Western blot of the reported target proteins. Protein extracts were obtained from tissue of control or teglicar-treated db/db mice (n = 8) subjected to analysis. B: Liver peroxisomal β-oxidation activity in controls and teglicar-treated mice.
FIG. 6. A: Representative Western blot of the reported target proteins. Protein extracts were obtained from tissue of control or teglicar-treated db/db mice (n = 8) subjected to analysis. B: Liver peroxisomal β-oxidation activity in controls and teglicar-treated mice.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Walter, 1976, Pyruvate carboxylase: intracellular localization and regulation, 239

Cited by

See all 99

Metadata

Authors
Conti, R., Mannucci, E., Pessotto, P., Tassoni, E., Carminati, P., Giannessi, F., & Arduini, A.
Affiliations
  • Sigma Tau (Italy) (IT)
  • Azienda Ospedaliero-Universitaria Careggi (IT)
  • Paolo Carminati, sigma-tau s.p.a, Rome, Italy
Corresponding author
Conti, Roberto
Venue
Diabetes
Published
2011-01-21
Volume
60
Issue
2
Pages
644-651
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W1986038576
Cited by
98
References
46
Citations by year
2026: 5 · 2025: 7 · 2024: 7 · 2023: 8 · 2022: 10 · 2021: 6 · 2020: 4 · 2019: 9 · 2018: 7 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 3 · 2013: 4 · 2012: 5
FWCI
5.25
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Florence Research (University of Florence) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
carnitine palmitoyltransferase 1, gluconeogenesis, glucose homeostasis, antidiabetic drugs, insulin sensitivity, hepatic triglycerides, type 2 diabetes, db/db mice, high-fat diet, ketone bodies, insulin tolerance test, hyperinsulinemic-euglycemic clamp
MeSH terms
Analysis of Variance, Animals, Carnitine, Carnitine O-Palmitoyltransferase, Diabetes Mellitus, Type 2, Dietary Fats, Gluconeogenesis, Glucose, Heart, Homeostasis, Insulin Resistance, Liver, Male, Myocardium, Rats, Sprague-Dawley, Area Under Curve, Hepatocytes, PPAR alpha, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.